Publications by authors named "Jacob Adashek"

Claim this Profile
A
Ag(e)nostic precision oncology therapy approvals across the years.
Matthew R Kudek, Jacob J Adashek, Razelle Kurzrock

Trends Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour-agnostic kinase inhibitors.
Jacob J Adashek, Mina Nikanjam, Razelle Kurzrock

Nat Rev Drug Discov· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene- and immune-targeted therapy combinations using dual-matched biomarkers for patient selection.
Daisuke Nishizaki, Razelle Kurzrock, Jacob J Adashek, Ki Hwan Kim, Hyo Jeong Lim

NPJ Precis Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the ugly.
Jacob J Adashek, Jillian A Moran, Dung T Le, Razelle Kurzrock

Cancer Metastasis Rev· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials.
Jia Liu, Max Farrow, Lesley Seymour, Jayesh Desai, Herbert H Loong, Jacob J Adashek

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toll-like receptor 3: a double-edged sword.
Marvin L Hsieh, Daisuke Nishizaki, Jacob J Adashek, Shumei Kato, Razelle Kurzrock

Biomark Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide.
Jacob J Adashek, Javier L Munoz, Razelle Kurzrock

Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia.
Jacob J Adashek, Max Brodsky, Mark J Levis

NPJ Precis Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnesses.
Mina Nikanjam, Kaitlyn Wells, Shumei Kato, Jacob J Adashek, Shanna Block

Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer Care in the Era of Artificial Intelligence.
Matthew Kurian, Jacob J Adashek, Howard Jack West

JAMA Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
If it's a target, it's a pan-cancer target: Tissue is not the issue.
Jacob J Adashek, Shumei Kato, Jason K Sicklick, Scott M Lippman, Razelle Kurzrock

Cancer Treat Rev· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysis.
Mahati Paravathaneni, Houssein Safa, Vidhu Joshi, Monica K Tamil, Jacob J Adashek

EClinicalMedicine· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer.
Jacob J Adashek, Chinmayi Pandya, Nicholas J Maragakis, Pradip De, Philip R Cohen

BMC Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity.
Jungah Lim, Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Jacob J Adashek

Cancer Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes.
Jacob J Adashek, Shumei Kato, Daisuke Nishizaki, Sarabjot Pabla, Mary K Nesline

Am J Cancer Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right place.
Jacob J Adashek, Razelle Kurzrock

NPJ Precis Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considering molecular alterations as pan-cancer tissue-agnostic targets.
Jacob J Adashek, Shumei Kato, Jason K Sicklick, Scott M Lippman, Razelle Kurzrock

Nat Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.
Aleksei Kondrashov, Surendra Sapkota, Aditya Sharma, Ivy Riano, Razelle Kurzrock, Jacob J Adashek

Pharmaceutics· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies.
Akram Mesleh Shayeb, Razelle Kurzrock, Jacob J Adashek, Shumei Kato

JCO Precis Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and prospects of CSF1R targeting for advanced malignancies.
Ann Moeller, Razelle Kurzrock, Gregory P Botta, Jacob J Adashek, Hitendra Patel

Am J Cancer Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics.
Jacob J Adashek, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Pradip De

Cancer Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers.
Blessie Elizabeth Nelson, Jacob J Adashek, Aakash Akshay Sheth, Vivek Subbiah

Mol Cancer Ther· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma.
Jacob J Adashek, Surendra Sapkota, Rodrigo de Castro Luna, Tanguy Y Seiwert

NPJ Precis Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics.
Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, Francesco Massari, Razelle Kurzrock, Jacob J Adashek

Pharmaceuticals (Basel)· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology?
Amol Gupta, Razelle Kurzrock, Jacob J Adashek

Cancers (Basel)· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis